SIGNAFUSE Bioactive Bone Graft Receives FDA Clearance

Rapid Unit Sales of Medical Masks to Account for Incremental Revenues in the Global Market Through the COVID-19 Crisis Period

Medical facilities are highly dependent on the use of medical masks during surgeries. The availability of different versions of mask for different applications across different end-users, such as ambulatory surgical centre’s, hospitals, dental settings, etc., are expected to fuel the growth of the medical mask market throughout the forecast period.

Proximie Raises $38m Series B Funding To Accelerate Its Expansion in U.S. and European Markets

F-Prime Capital led financing, joined by Questa Capital, Eight Roads, and Maverick Ventures

RhoVac Reports to Mount Sinai Hospital in New York Join Phase IIb Study in Prostate Cancer

The participation of Mount Sinai was directly caused by the FDA approval of RhoVac's Fast Track Designation.

June 25, 2020

SIGNAFUSE Bioactive Bone Graft in a new strip format receives FDA Clearance reports Bioventus. The strips consist of 55% bioglass by weight and have been shown to induce higher levels of osteoblast differentiation compared to other synthetic bone graft strips.1

SIGNAFUSE Bioactive bone graft has been available as a putty since 2014; the new strips hydrate rapidly and provide exceptional handling properties for intraoperative flexibility. They come in multiple sizes ranging from 25 to 200 millimeters in length, with the longer strips providing a great option for large, multilevel procedures.

The biphasic mineral in SIGNAFUSE is composed of 60% hydroxyapatite and 40% beta- tricalcium phosphate; a ratio supported by multiple prospective2 and randomized controlled trials.3-5

“We are excited to expand our portfolio of bone graft solutions with the SIGNAFUSE Bioactive Bone Graft strip,” said Megan Osorio, Vice President, Marketing, Bioventus. “Apart from the ideal combination of biomaterials that contribute to healing, and best-in-class handling, this product is unique in that it offers a great solution for patients that require more significant interventions such as spinal deformity correction.”

“We also believe SIGNAFUSE in the strip format will provide efficiencies for the hospital, either by opening fewer packages or cost savings opportunities vs. alternative grafts,” added John Nosenzo, Chief Commercial Officer, Bioventus.

The new strip format of SIGNAFUSE will be available in Q3 from our distributor partners across the country.



Related Articles